Glutamate as a therapeutic target in psychiatric disorders (Q35847653)

10 August 2017

1 reference

title

Glutamate as a therapeutic target in psychiatric disorders (English)

1 reference

10 August 2017

Javitt DC

1

1 reference

PubMed ID

15278097

10 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

10 August 2017

1 reference

10 August 2017

9

1 reference

10 August 2017

984-97, 979

1 reference

10 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.mp.4001551

10 August 2017

0 references

cites work

The neocortex. An overview of its evolutionary development, structural organization and synaptology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Excitatory amino acid transporters: keeping up with glutamate.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Biophysical basis of brain activity: implications for neuroimaging

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Does glutamate image your thoughts?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Sodium-coupled neutral amino acid (System N/A) transporters of the SLC38 gene family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Glutamine uptake by neurons: interaction of protons with system a transporters.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

High dose glycine nutrition affects glial cell morphology in rat hippocampus and cerebellum.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Chronic high-dose glycine nutrition: effects on rat brain cell morphology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Subunit- and site-specific pharmacology of the NMDA receptor channel

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Expression mechanisms underlying long-term potentiation: a postsynaptic view

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

NMDA and non-NMDA receptors mediate visual responses of neurons in the cat's lateral geniculate nucleus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

NMDA receptor-mediated dendritic spikes and coincident signal amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Specific roles of NMDA and AMPA receptors in direction-selective and spatial phase-selective responses in visual cortex.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Neurotransmitter receptors mediating excitatory input to cells in the cat lateral geniculate nucleus. I. Lagged cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Visual experience and deprivation bidirectionally modify the composition and function of NMDA receptors in visual cortex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

A unified model of NMDA receptor-dependent bidirectional synaptic plasticity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Clustering and anchoring mechanisms of molecular constituents of postsynaptic scaffolds in dendritic spines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Molecular mechanisms of glutamate receptor clustering at excitatory synapses.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Activity-dependent recruitment of extrasynaptic NMDA receptor activation at an AMPA receptor-only synapse.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Mobile NMDA receptors at hippocampal synapses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Glycine potentiates the NMDA response in cultured mouse brain neurons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

High-affinity transport of gamma-aminobutyric acid, glycine, taurine, L-aspartic acid, and L-glutamic acid in synaptosomal (P2) tissue: a kinetic and substrate specificity analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Neuronal and glial glycine transporters have different stoichiometries

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

ATA2 is predominantly expressed as system A at the blood-brain barrier and acts as brain-to-blood efflux transport for L-proline

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The origin and turnover of D-serine in brain.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Purification of serine racemase: biosynthesis of the neuromodulator D-serine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

A novel alanine-insensitive D-serine transporter in rat brain synaptosomal membranes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The AMPAR subunit GluR2: still front and center-stage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Silent glutamatergic synapses in the mammalian brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Member of the Ampakine class of memory enhancers prolongs the single channel open time of reconstituted AMPA receptors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

NMDA-induced phosphorylation and regulation of mGluR5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

NMDA receptor hypofunction model of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The NMDA antagonist model for schizophrenia: promise and pitfalls.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The glutamatergic dysfunction hypothesis for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

PHARMACOLOGIC EFFECTS OF CI-581, A NEW DISSOCIATIVE ANESTHETIC, IN MAN.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Neuropsychological function in schizophrenia. Selective impairment in memory and learning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Synaptic plasticity and learning: selective impairment of learning rats and blockade of long-term potentiation in vivo by the N-methyl-D-aspartate receptor antagonist AP5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Model psychoses and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The PCP psychosis: prolonged intoxication or drug-precipitated functional illness?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Effects of ketamine in normal and schizophrenic volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Phencyclidine in combination with d-amphetamine: differential effects on acquisition and performance of response chains in monkeys.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Clinical and sensorimotor gating effects of ketamine in normals

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Behavioral effects of chronic phencyclidine in monkeys

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Mice with reduced NMDA receptor expression display behaviors related to schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Differential effects of enrichment on learning and memory function in NR2B transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Object retrieval/detour deficits in monkeys produced by prior subchronic phencyclidine administration: evidence for cognitive impulsivity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Ketamine--can chronic use impair memory?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Long-term changes in brain following continuous phencyclidine administration: an autoradiographic study using flunitrazepam, ketanserin, mazindol, quinuclidinyl benzilate, piperidyl-3,4-3H(N)-TCP, and AMPA receptor ligands.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Glutamate receptor dysfunction and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Clozapine-induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: microdialysis and electrophysiological studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The role of glycineB binding site and glycine transporter (GlyT1) in the regulation of [3H]GABA and [3H]glycine release in the rat brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Inhibition of striatal dopamine release by glycine and glycyldodecylamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Discovery and SAR of org 24598-a selective glycine uptake inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Chronic elevation of brain-derived neurotrophic factor by ampakines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Clozapine plus lamotrigine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Different roles of group I and group II metabotropic glutamate receptors on phencyclidine-induced dopamine release in the rat prefrontal cortex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The metabotropic glutamate receptors: structure, activation mechanism and pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Distribution of mGluR1alpha and mGluR5 immunolabeling in primate prefrontal cortex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Group I metabotropic glutamate receptors in the monkey striatum: subsynaptic association with glutamatergic and dopaminergic afferents.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Positive association of the AMPA receptor subunit GluR4 gene (GRIA4) haplotype with schizophrenia: linkage disequilibrium mapping using SNPs evenly distributed across the gene region

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The role of glutamate receptors in antipsychotic drug action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Effects of dofetilide on cardiovascular tissues from normo- and hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Amyloid beta protein enhances the clearance of extracellular L-glutamate by cultured rat cortical astrocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Evaluation of cycloserine in the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

d-Cycloserine enhances implicit memory in Alzheimer patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Loss of glycine-dependent radioligand binding to the N-methyl-D-aspartate-phencyclidine receptor complex in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Psychiatric uses of antiepileptic treatments

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Antidepressant effects of ketamine in depressed patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Glutamate and depression: clinical and preclinical studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Antidepressant mechanisms: functional and molecular correlates of excitatory amino acid neurotransmission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The N-methyl-D-aspartate receptor, synaptic plasticity, and depressive disorder. A critical review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The neurobiology of stress: from serendipity to clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

NMDA receptor antagonist treatment induces a long-lasting increase in the number of proliferating cells, PSA-NCAM-immunoreactive granule neurons and radial glia in the adult rat dentate gyrus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Long-term imipramine effects are prevented by NMDA receptor blockade.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

The NMDA-receptor antagonist MK-801 selectively disrupts reversal learning in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

NMDA receptors in the rat orbital prefrontal cortex are involved in guidance of instrumental behaviour under reversal conditions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

D-cycloserine, a partial NMDA receptor-associated glycine-B site agonist, enhances reversal learning, but a cholinesterase inhibitor and nicotine has no effect.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Adjunctive high-dose glycine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001551

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001551

1 reference

10 August 2017

1 reference

PubMed ID

15278097